SCNI vs. FNCH, ELOX, GMDAQ, WINT, ACORQ, SQZ, PKBO, IGNY, GNCA, and ALVO
Should you be buying Scinai Immunotherapeutics stock or one of its competitors? The main competitors of Scinai Immunotherapeutics include Finch Therapeutics Group (FNCH), Eloxx Pharmaceuticals (ELOX), Gamida Cell (GMDAQ), Windtree Therapeutics (WINT), Acorda Therapeutics (ACORQ), SQZ Biotechnologies (SQZ), Peak Bio (PKBO), Ignyte Acquisition (IGNY), Genocea Biosciences (GNCA), and Alvotech (ALVO). These companies are all part of the "biological products, except diagnostic" industry.
Finch Therapeutics Group (NASDAQ:FNCH) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.
Finch Therapeutics Group has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.45, meaning that its stock price is 145% more volatile than the S&P 500.
Scinai Immunotherapeutics has lower revenue, but higher earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.
Finch Therapeutics Group's return on equity of 0.00% beat Scinai Immunotherapeutics' return on equity.
21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Finch Therapeutics Group received 10 more outperform votes than Scinai Immunotherapeutics when rated by MarketBeat users.
In the previous week, Finch Therapeutics Group and Finch Therapeutics Group both had 2 articles in the media. Finch Therapeutics Group's average media sentiment score of 1.44 beat Scinai Immunotherapeutics' score of 0.96 indicating that Scinai Immunotherapeutics is being referred to more favorably in the news media.
Summary
Scinai Immunotherapeutics beats Finch Therapeutics Group on 7 of the 11 factors compared between the two stocks.
Get Scinai Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCNI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scinai Immunotherapeutics Competitors List
Related Companies and Tools
